Pyelonephritis

Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program

Retrieved on: 
Monday, October 3, 2022
Area studies, Ponce Health Sciences University, Degenerative disease, Tuberculosis, Science, U.S. Securities and Exchange Commission, Adult, Physician, Center for Epidemiologic Studies Depression Scale, Nasdaq, Research, Infection, Pyelonephritis, NTM, Rheumatology, Mentorship, FDA, MPH, HBR, MDR, Tebipenem, Q&A, Public health, Oregon Health and Science University Center for Women's Health, Bacteria, Therapy, Cutis verticis gyrata, Oregon Health & Science University, Bronchiectasis, OHSU, Patient, Division, Center, Publication, Universal Music Publishing Group, GLOBE, Ophthalmology, Pharmaceutical industry, Spero, MD

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a virtual R&D event on Thursday, October 6, 2022, at 11:30 a.m. Eastern Time.

Key Points: 
  • The virtual event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH, from the Division of Infectious Disease, OHSU Medical School.
  • During his presentation, Dr. Winthrop will discuss the etiology, unmet medical need, and treatment landscape of non-tuberculous mycobacteria (NTM) pulmonary disease.
  • Members of the Spero management team will provide an overview of the development program for SPR720, a potential novel first line oral therapy for NTM infections.
  • Spero Therapeuticsis developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

Retrieved on: 
Thursday, September 22, 2022
Benchmark, Adult, Carbapenem, Meiji, Infection, Sinusitis, Biomedical Advanced Research and Development Authority, COVID-19, FDA, Food, Otitis media, Administration, Gram, U.S. Securities and Exchange Commission, Company, Genta (company), GSK, Access, Degenerative disease, AP, Therapy, Program, Patient, Cyprus Securities and Exchange Commission, Pneumonia, Technology, Pyelonephritis, Human services, QIDP, Tebipenem, Bacteria, Annual report, Hart–Scott–Rodino Antitrust Improvements Act, Urinary tract infection, Research, HBR, Marketing, Cutis marmorata telangiectatica congenita, Food and Drug Administration, Gram-negative bacteria, Disease, Pharmaceutical industry, Spero

LONDON and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- GSK (LSE/NYSE: GSK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced they have entered into an exclusive license agreement for Spero’s late-stage antibiotic asset, tebipenem HBr. Tebipenem HBr is being developed as the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain bacteria.

Key Points: 
  • In connection with the license agreement and pursuant to a stock purchase agreement between GSK and Spero, GSK has agreed to make a $9 million common stock investment in Spero, purchasing 7,450,000 shares of Speros common stock at a purchase price of approximately $1.20805 per share, not to exceed 19.99% beneficial ownership of Spero by GSK and its affiliates.
  • The closing of the equity investment is conditioned upon the effectiveness of the license following Hart-Scott-Rodino clearance.
  • As of June 30, 2022, Spero had cash, cash equivalents, and marketable securities of $45.4 million.
  • If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval in the United States.

Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

Retrieved on: 
Thursday, September 15, 2022
Adult, American University, MPH, American University of Beirut, Roivant Sciences, Time, Joint Medical Service (Germany), American College, COVID-19, Infection, Risk, FDA, Urinary tract infection, U.S. Securities and Exchange Commission, Basilea Pharmaceutica, Degenerative disease, Partnership, CMO, Therapy, Medical Affairs Bureau, Program, Patient, University, MBA, Bristol Myers Squibb, Physician, American College of Physicians, Tebipenem, Nasdaq, Stanford University School of Medicine, Novartis, Internal medicine, Johns Hopkins University, Pyelonephritis, Research, GLOBE, HBR, Cutis verticis gyrata, Infectious Diseases Society of America, Robert Wood Johnson Medical School, Pharmaceutical industry, MD, Bayer, Aleksei Lysov, Spero

CAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO).

Key Points: 
  • CAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO).
  • Kamal joins Spero with an impressive track record of building and leading successful anti-infective franchises, said Ankit Mahadevia, MD, Chief Executive Officer of Spero Therapeutics.
  • I am thrilled to have Kamal on our management team and look forward to working together.
  • Dr. Hamed has over 20 years of experience leading various anti-infective clinical development programs in antibacterials, antivirals, antimalarials, and antifungals.

Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split

Retrieved on: 
Thursday, September 15, 2022
Fosfomycin, Tablet, Nasdaq, Infection, COVID-19, BID, Food, Computershare, U.S. Securities and Exchange Commission, Annual, Company, Therapy, Bangladesh Securities and Exchange Commission, CUSIP, Regulation of tobacco by the U.S. Food and Drug Administration, Exercise, Pyelonephritis, Private Securities Litigation Reform Act, Board of directors, NASDAQ, Bronchopneumonia, Urinary tract infection, Board, Security (finance), GLOBE, Marketing, The Cutie Mark Chronicles, Merck, Food and Drug Administration, Pharmaceutical industry

Nabriva Therapeutics Board of Directors subsequently determined that the reverse stock split was necessary for the Company to comply with the Bid Price Rule and approved the implementation of the reverse stock split at a ratio of 1-for-25 ordinary shares.

Key Points: 
  • Nabriva Therapeutics Board of Directors subsequently determined that the reverse stock split was necessary for the Company to comply with the Bid Price Rule and approved the implementation of the reverse stock split at a ratio of 1-for-25 ordinary shares.
  • Nabriva Therapeutics ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol NBRV and the new CUSIP number for Nabriva Therapeutics ordinary shares following the reverse stock split is G63637 139.
  • The reverse stock split will also apply to ordinary shares issuable upon the exercise of Nabriva Therapeutics outstanding restricted stock units, stock options and warrants with a proportional increase in the respective exercise prices, as applicable.
  • Additional information regarding the reverse stock split can be found in Nabriva Therapeutics definitive proxy statement filed with the Securities and Exchange Commission on July 11, 2022.

Spero Therapeutics to Present at Upcoming Investor Conference

Retrieved on: 
Wednesday, September 7, 2022
Spero, Degenerative disease, Therapy, HBR, Infection, Tebipenem, Cutis verticis gyrata, GLOBE, Conference, Nasdaq, FDA, Pyelonephritis, Adult, MDR, Patient, Pharmaceutical industry

Webcasts of the presentations may also be accessed through Spero Therapeutics website ( www.sperotherapeutics.com ) on the Events and Presentations page under the Investors and Media tab.

Key Points: 
  • Webcasts of the presentations may also be accessed through Spero Therapeutics website ( www.sperotherapeutics.com ) on the Events and Presentations page under the Investors and Media tab.
  • Spero Therapeuticsis a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.
  • Spero Therapeuticsis developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
  • Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat multi-drug resistant Gram-negative infections in the hospital setting.

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Retrieved on: 
Tuesday, September 6, 2022
Type, Partnership, COVID-19, Biomedical Advanced Research and Development Authority, NDA, Program, Urinary tract infection, Research, Degenerative disease, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, HBR, Infection, Tebipenem, North Carolina Department of Health and Human Services, Administration, Cutis verticis gyrata, Food, Department, U.S. Securities and Exchange Commission, SPA, GLOBE, Nasdaq, FDA, Pyelonephritis, CRL, Adult, Risk, Endpoint security, Marketing, Patient, Medical device, Pharmaceutical industry, Spero

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today provided an update on its tebipenem HBr program following the receipt of minutes from a recent Type A meeting with the U.S. Food and Drug Administration (FDA), discussing steps required for resubmission of the New Drug Application (NDA) for tebipenem HBr for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today provided an update on its tebipenem HBr program following the receipt of minutes from a recent Type A meeting with the U.S. Food and Drug Administration (FDA), discussing steps required for resubmission of the New Drug Application (NDA) for tebipenem HBr for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.
  • We are pleased to have found common ground with the FDA on the regulatory path forward for tebipenem HBr, said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.
  • With this clarity, we are better positioned to advance the program as we work to establish and nurture external partnerships for further development.
  • However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022
Urinary tract infection, Tablet, Therapy, Food and Drug Administration, NASDAQ, Tuberculosis verrucosa cutis, Food, Fosfomycin, Pyelonephritis, Infection, GLOBE, Conference, Bronchopneumonia, Merck, Pharmaceutical industry

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 24th Annual Global Investment Conference.

Key Points: 
  • DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 24th Annual Global Investment Conference.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Global Urinary Tract Infection Testing Market Report (2022 to 2030) - Size, Share & Trends Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 30, 2022
Health, General Health, International Diabetes Federation, COVID-19, U.S. Department of Defense Strategy for Operating in Cyberspace, NCBI, Urinary tract infection, Human services, Ageing, Awareness, Urology, IDF, Scope, Man, Recurrence, Incidence, Physician, Diabetes, UTI, Investment, POC, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Prevalence, Pyelonephritis, Adult, Risk, Woman, Growth, Industry, Life, Adoption, Pharmaceutical industry, Medical imaging

Urinary tract infection is becoming a common global concern.

Key Points: 
  • Urinary tract infection is becoming a common global concern.
  • According to research studies, UTI occurs in one in five adult women at some point in their life.
  • Genetic and cultural factors may influence its prevalence; for instance, in South Korea, the incidence of pyelonephritis is around 59/10,000.
  • This can be attributed to better reimbursement facilities and a rise in the adoption of novel diagnostic products due to increased awareness
    Chapter 3 Urinary Tract Infection Market Variables, Trends, and Scope

Stramsen Biotech Inc. Announced Mr. Joe Meuth as The Chairman of the Board of Directors and Mr. Peter Olsen as President and CFO

Retrieved on: 
Thursday, August 18, 2022
Hewlett-Packard, Prostate cancer, Refugee, HP, Ernst, Poverty, Pyelonephritis, Board, Business, Cyprus Securities and Exchange Commission, Baylor University, Master, Merrill (company), Diabetes, Patient, Business administration, Company, Biotechnology, Defense Finance and Accounting Service, CPA, Safety, Board of directors, Texas A&M University, DeVry University, University, MBA, HIV, Master of Accountancy, Medicine, Rice University, Organization, Pharmaceutical industry, Management, Young, Leukemia, Innospec, Cancer

HOUSTON, Aug. 18, 2022 /PRNewswire/ -- Stramsen Biotech Inc. is a Houston, Texas -based Biotechnology Company that currently has eleven new natural plant-based drug candidates for clinical development. The medicine candidates are for different diseases including HIV / AIDS, Cancer, Wound care, Leukemia, Cardiovascular, neuropathy, prostate cancer, Diabetes, kidney infections and for bone and joint pain. Due to rising resistance and safety concerns to some synthetic drugs, people around the world are increasingly turning to natural plant-based drugs / medicines for their healthcare needs. Currently, 40% of all medicines that are prescribed to all patients in the world are derived from medicinal plants, and they are rigorously tested in clinical trials. the Company will start exploring all fundraising options including going public and filing prospectus form S-1 with the securities and exchange commission.

Key Points: 
  • HOUSTON, Aug. 18, 2022 /PRNewswire/ -- Stramsen Biotech Inc. is a Houston, Texas -based Biotechnology Company that currently has eleven new natural plant-based drug candidates for clinical development.
  • The medicine candidates are for different diseases including HIV / AIDS, Cancer, Wound care, Leukemia, Cardiovascular, neuropathy, prostate cancer, Diabetes, kidney infections and for bone and joint pain.
  • Mr. Joe Meuth has been appointed as the Chairman of the Board of Directors of Stramsen Biotech Inc. Mr. Joe Meuth holds three university degrees from three different universities.
  • Mr. Peter Olsen is the new President of Stramsen Biotech Inc. Mr. Olsen has bachelor's degree in Business Management from DeVry University.

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

Retrieved on: 
Tuesday, August 9, 2022
FDA, Spero, HBR, GLOBE, Tebipenem, Pyelonephritis, Patient, Infection, Degenerative disease, Therapy, Tuberculosis verrucosa cutis, Nasdaq, ID, Adult, Pharmaceutical industry

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m.
  • ET to report its second quarter 2022 financial results and provide an update on its business and pipeline.
  • To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13731565.
  • Spero Therapeuticsis developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.